Efficacy of AS04-adjuvanted HPV-16/18 vaccine against clearance of incident HPV infections: Pooled analysis of data from the CVT and PATRICIA randomized trials
Menée à partir des données de 2 essais randomisés incluant au total 981 femmes vaccinées contre le papillomavirus humain et 1 108 témoins, cette étude évalue l'efficacité du vaccin "AS04-HPV-16/18" contre des infections à HPV non ciblées et les lésions cervicales associées
Clinical trial data and real-world evidence suggest the AS04-adjuvanted HPV-16/18 (AS04-HPV-16/18) vaccine provides nearly 90% protection against cervical intraepithelial neoplasia grade 3 or greater (CIN3+) irrespective of type, among females vaccinated prior to sexual debut. This high efficacy is not fully explained by cross-protection. Although AS04-HPV-16/18 vaccination does not impact clearance of prevalent infections, it may accelerate clearance of newly acquired infections. We pooled data from two large-scale randomized controlled trials to evaluate efficacy of the AS04-HPV-16/18 vaccine against clearance of non-targeted incident infections. Results of our analysis do not suggest an effect in expediting clearance of incident infections.